Table 1.
Patient characteristics
| Number | 39 |
| Age, median (range) | 63 (36–78) |
| Sex | |
| Male | 34 |
| Female | 5 |
| ECOG | |
| 0 | 10 |
| 1 | 29 |
| Liver cirrhosis | |
| Yes | 26 |
| No | 13 |
| Cause of liver disease | |
| HBV | 7 |
| HCV | 21 |
| Baseline Child–Pugh score | |
| 5 | 16 |
| 6 | 7 |
| 7 | 3 |
| BCLC stage | |
| B | 9 |
| C | 30 |
| Extrahepatic disease | |
| Yes | 17 |
| No | 22 |
| Prior sorafenib | |
| Yes/no | 27/12 |
| Discontinue due to PD/intolerance | 23/4 |
| Other systemic therapies | 10 |
| Other previous interventions | |
| TACE | 13 |
| Surgery | 5 |
| Ablation | 6 |
| Outcome analysis | |
| Non-evaluable | 5 |
| Non-responder | 15 |
| Responder | 19 |
| CR | 1 |
| PR | 7 |
| SD | 15 |
| PD | 11 |
ECOG Eastern Cooperative Oncology Group, HBV Hepatitis B virus, HCV Hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, PD progressive disease, TACE transarterial chemoembolization, CR complete response, PR partial response, SD stable disease